Parvus Therapeutics Inc.

Parvus Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary pMHC nanomedicine drug candidates (Navacims) designed to treat autoimmune diseases. Its mission is to cure autoimmune disease by restoring organ-specific immune tolerance without compromising normal immune function, shifting the treatment paradigm toward Navacim-directed immune regulation to avoid the non-specific immune suppression associated with current therapies.